After four weeks, half the total scores on both the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), used to measure behavioral symptoms, and the ADAS-cog in the two groups decreased when compared to the baseline.
Wu et al., BEHAVE-AD improved 73.1% versus 42.3 of the 2015 (a) placebo group.
At the end of the trial both groups showed improvement in cognition and in behavioral symptoms (assessed using the Behavioral Pathology in Alzheimer's Disease Rating Scale, BEHAVE-AD ), but the improvement was significantly greater among patients who received adjunctive rTMS.
Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale.
testing, it is also equipped with functions that help them carry out other tests, namely HDS-R, a simplified dementia screening test, and BEHAVE-AD
, whichassesses peripheral symptoms of dementia based on information provided by caregivers.
can be done in as little as 10 minutes once the test-giver is familiar with the format, he said.
De Deyn and his associates found that 722 patients who had received risperidone had significantly greater improvement from baseline on the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD
) and the Cohen-Mansfield Agitation Inventory (CMAI) at week 4 through the end of treatment at week 12 than did 428 patients who received placebo (Clin.
Clinical improvement, defined as a 30% or greater reduction in scores on the Behavior Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD
), was seen in 54% of patients in the risperidone group, 63% in the haloperidol group, and 47% in the placebo group.
OUTCOMES MEASURED * The primary outcome was clinically significant improvement of disturbing behavior defined as a 30% or greater change on the Behavior Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD
) total score.
Inclusion criteria were as follows: a) met the criteria for probable AD proposed by the National Institute of Neurological and Communicative Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA);  b) 60-80 years of age; c) minimum of 5 years of education; d) total score on Mini-Mental State Examination(MMSE)  of less than 24; e) total score on Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD
)  of greater than 8; e) no history of epilepsy, stroke, or major head trauma; f) no severe physical illness or implants which could limit the use of rTMS; and g) had not taken antipsychotic medications or other drugs affecting mental activity in the previous month.
At a dose of about 1 mg per day, risperidone also has significantly greater efficacy than haloperidol (Haldol) as shown by results of BEHAVE-AD
and CMAI--beginning around week 4-6 of treatment--in two trials of treatment for agitation and aggression in patients with dementia (Neurology 1999;53:946-55; Am.
Among patients who scored higher than 1 on the wandering portion of the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD
) scale, those taking 1 mg of risperidone had a hazard ratio of 0.28, so they were 72% less likely to fall, compared with patients receiving the placebo.